Thymol-based derivatives as anticancer agents: design, synthesis, biological evaluation, and molecular docking studies
Bioorganic Chemistry · 2026-11 · 183 · 110587
DOI: 10.1016/j.bioorg.2026.110587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Abdelmoujoud Faris und 14 weiteren Autor:innen. Beteiligte Einrichtung: LIMAS, Department of Chemical Sciences, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez 30000, Morocco. Hauptthemen laut MEDLINE: Antineoplastic Agents, Molecular Docking Simulation, Drug Design, Thymol. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione dell'Università e della Ricerca, Ministero dell’Istruzione, dell’Università e della Ricerca.
Abstract (Originalsprache)
Seventeen thymol-based derivatives (TM1-7, TBr1-2, TCl1-4, and TF1-4) were designed and synthesized by esterification with halo- and non-halogenated cinnamoyl molecules employing a key-step coupling reaction. All derivatives were chemically characterized (1H NMR, 13C NMR, HR-MS, and HPLC analysis) and evaluated for their potential anticancer properties. The anti-proliferative effectiveness was assessed using an MTT assay against four cancer cell lines (U87MG, SHSY-5Y, MDA-MB-231, and JIMT1) and human dermal fibroblasts (HDFa) compared to Triton X-100. Among the thymol-based derivatives, TM7 and TBr1 showed the highest cytotoxic activity against U87MG cells showing IC50 equal to 0.014 μM and 0.054 μM, respectively. Compounds TBr1 and TBr2 exhibited selective cytotoxic activity toward neuroblastoma (SH-SY5Y) cancer cells displaying IC50 of 5.123 μM and 1.103 μM, respectively. On the other hand, TM7, TBr1, and TBr2 showed IC50 higher than 200 μM toward MDA-MB-231 and JIMT1 cells. Highest anti-proliferative effect was detected with TBr2 in both breast cancer cell lines and TBr1 and TBr2 induced apoptosis more rapidly than TM7, especially in MDA-MB-231 cells. Cells used in this study depend on FAK and PI3Kα signaling for survival and proliferation, and inhibition of these pathways reduces viability and induces apoptosis. To support their potential as molecular targets, in silico studies including docking, 100 ns MD simulations, and ADMET analysis were performed. TBr1 and TBr2 showed stronger predicted binding and more stable in silico interactions with FAK and PI3Kα, suggesting that these kinases may represent candidate molecular partners involved in their anticancer activity, whereas TM7 displayed a more favorable predicted pharmacokinetic profile. These computational findings are hypothesis-generating and have not yet been confirmed by biochemical target-engagement assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LIMAS, Department of Chemical Sciences, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez 30000, Morocco.
- Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Via dei Vestini 31, Scalo, 66100 Chieti, Italy.
- Institute of Clinical and Translational Research, Biomedical Research Center, Slovak Academy of Sciences, Dubravska cesta 9, 84505 Bratislava, Slovakia.
- Department of Medical Biology, Faculty of Medicine, Atatürk University, Erzurum, Turkiye.
- Department of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum, Turkiye.
- Department of Internal Medicine, Erzurum Regional Training and Research Hospital, Health Sciences University, Erzurum, Turkiye.
Förderung
- Ministero dell'Istruzione dell'Università e della Ricerca
- Ministero dell’Istruzione, dell’Università e della Ricerca
Zitieren
APA
Faris, A., Di Rienzo, A., Klena, L., Krizanova, O., Turkez, H., Men, D. E., Arslan, E., Arslan, M. E., Cadirci, K., Kim, W., Mardinoglu, A., Valentinuzzi, S., Del Boccio, P., Di Stefano, A., & Cacciatore, I. (2026). Thymol-based derivatives as anticancer agents: design, synthesis, biological evaluation, and molecular docking studies. Bioorganic Chemistry, 183, 110587. https://doi.org/10.1016/j.bioorg.2026.110587
Vancouver
Faris A, Di Rienzo A, Klena L, Krizanova O, Turkez H, Men DE, et al. Thymol-based derivatives as anticancer agents: design, synthesis, biological evaluation, and molecular docking studies. Bioorganic Chemistry. 2026;183:110587. doi:10.1016/j.bioorg.2026.110587
BibTeX
@article{Faris2026,
author = {Faris, Abdelmoujoud and Di Rienzo, Annalisa and Klena, Ladislav and Krizanova, Olga and Turkez, Hasan and Men, Dilara Esra and Arslan, Elif and Arslan, Mehmet Enes and Cadirci, Kenan and Kim, Woonghee and Mardinoglu, Adil and Valentinuzzi, Silvia and Del Boccio, Piero and Di Stefano, Antonio and Cacciatore, Ivana},
title = {Thymol-based derivatives as anticancer agents: design, synthesis, biological evaluation, and molecular docking studies},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {183},
pages = {110587},
doi = {10.1016/j.bioorg.2026.110587}
}
EUVIMED